• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma
【24h】

A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma

机译：吸入性糖皮质激素治疗哮喘的安全性和有效性研究进展

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Asthma is a chronic inflammatory disease characterized by symptoms of cough, dyspnea, chest tightness, and wheeze. Inhaled corticosteroids (ICS) have been recommended as initial therapy in the treatment of persistent asthma in all guidelines, as they have been shown to reduce morbidity and mortality. However, high-dose regimens and long-term use of ICS may be associated with a variety of side effects, similar to those observed with systemic corticosteroid therapy. These side effects include impaired growth in children, osteoporosis, fractures, glaucoma, cataracts, and skin thinning. The current recommendations on ICS use in asthma management will be reviewed in this article with a view to highlight treatment strategies that strike an optimal balance between safety and efficacy.
机译：哮喘是一种慢性炎症性疾病，其特征是咳嗽，呼吸困难，胸闷和喘息。在所有指南中，均已建议吸入性糖皮质激素（ICS）作为持续性哮喘治疗的初始治疗方法，因为它已被证明可以降低发病率和死亡率。但是，大剂量方案和长期使用ICS可能会导致多种副作用，类似于全身性皮质类固醇激素疗法所观察到的副作用。这些副作用包括儿童生长受损，骨质疏松，骨折，青光眼，白内障和皮肤变薄。本文将对有关在哮喘管理中使用ICS的当前建议进行综述，以突出强调在安全性和功效之间达到最佳平衡的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号